Journal of Visualized Experiments

Crystallization and structure determination of an enzyme:substrate complex by serial crystallography in a versatile microfluidic chip

--Manuscript Draft--

Article Type:	Invited Methods Article - Author Produced Video
Manuscript Number:	JoVE61972R2
Full Title:	Crystallization and structure determination of an enzyme:substrate complex by serial crystallography in a versatile microfluidic chip
Corresponding Author:	Claude Sauter FRANCE
Corresponding Author's Institution:	
Corresponding Author E-Mail:	c.sauter@ibmc-cnrs.unistra.fr
Order of Authors:	Raphaël de Wijn
	Kévin Rollet
	Vincent Olieric
	Oliver Hennig
	Nicola Thome
	Camille Nous
	Caroline Paulus
	Bernard Lorber
	Heike Betat
	Mario Mörl
	Claude Sauter
Additional Information:	
Question	**Response**
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US$3000)
Please specify the section of the submitted manuscript.	Biochemistry
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the Author License Agreement
Please provide any comments to the journal here.	

TITLE:

Crystallization and structural determination of an enzyme:substrate complex by serial crystallography in a versatile microfluidic chip

AUTHORS AND AFFILIATIONS:

Raphaël de Wijn[1,5], Kévin Rollet[1,2], Vincent Olieric[3], Oliver Hennig[2], Nicola Thome[1], Camille Noûs[1], Caroline Paulus[1], Bernard Lorber[1], Heike Betat[2], Mario Mörl[2], Claude Sauter[1]

[1]Université de Strasbourg, Architecture et Réactivité de l'ARN, UPR 9002, CNRS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
[2]Biochemistry and Molecular Biology, Institute for Biochemistry, Leipzig University, Leipzig, Germany
[3]Paul Scherrer Institute, Swiss Light Source, X06DA beamline, Villigen, Switzerland
[4]Present address: European XFEL GmbH, Schenefeld, Germany

raphael.de.wijn@xfel.eu
k.rollet@ibmc-cnrs.unistra.fr
vinvent.olieric@psi.ch
oliver.hennig@uni-leipzig.de
nici7@online.de
camille.nous@cogitamus.fr
c.paulus@unistra.fr
b.lorber@ibmc-cnrs.unistra.fr
heike.betat@uni-leipzig.de
mario.moerl@uni-leipzig.de
c.sauter@ibmc-cnrs.unistra.fr

Corresponding Author:
Claude Sauter
c.sauter@ibmc-cnrs.unistra.fr

KEYWORDS:

crystallization, serial crystallography, 3D structure, counter-diffusion, ChipX, microfluidics, CCA-adding enzyme, soaking, seeding

SUMMARY:

A versatile microfluidic device is described that enables the crystallization of an enzyme using the counter-diffusion method, the introduction of a substrate in the crystals by soaking, and the 3D structure determination of the enzyme:substrate complex by a serial analysis of crystals inside the chip at room temperature.

ABSTRACT:

The preparation of well diffracting crystals and their handling before their X-ray analysis are two critical steps of biocrystallographic studies. We describe a versatile microfluidic chip that

enables the production of crystals by the efficient method of counter-diffusion. The convection-free environment provided by the microfluidic channels is ideal for crystal growth and useful to diffuse a substrate into the active site of the crystalline enzyme. Here we applied this approach to the CCA-adding enzyme of the psychrophilic bacterium *Planococcus halocryophilus* in the presented example. After crystallization and substrate diffusion/soaking, the crystal structure of the enzyme:substrate complex was determined at room temperature by serial crystallography and the analysis of multiple crystals directly inside the chip. The whole procedure preserves the genuine diffraction properties of the samples because it requires no crystal handling.

INTRODUCTION:

Crystallography is a method to decipher the 3D architecture of biological macromolecules. The latter is important to understand how an enzyme selects and processes its substrates. The determination of a crystal structure requires the crystallization of the target macromolecule and the conditioning of the crystals for their analysis by X-ray diffraction[1]. Both crystal preparation and handling are crucial but delicate steps that can affect crystal quality and diffraction properties, and, thus, the resolution (i.e., the accuracy) of the resulting 3D structure. To facilitate the preparation of high-quality crystals and eliminate unnecessary handling to preserve their diffraction properties, we designed a user-friendly and versatile microfluidic device called ChipX[2–4].

In this article, we will demonstrate how to load the protein solution into ChipX channels using conventional laboratory material to prepare crystals by counter-diffusion. This crystallization method provides an efficient screening of supersaturation and of potential nucleation conditions along the microfluidic channels containing the enzyme solution due to the concentration gradient generated by the diffusion of the crystallizing agent[5, 6].

The chip setup is simple, it uses only standard laboratory pipets and does not require any costly equipment. When crystals have grown in ChipX, ligands of the enzyme can be introduced by diffusion. Diffraction data are then collected at room temperature on a series of crystals contained in the channels of the chip using a synchrotron X-ray source. The structural study described here led to the determination of structures of a tRNA maturation enzyme in its apo form and in complex with an analogue of its CTP substrate introduced by soaking. This protein called CCA-adding enzyme polymerizes the CCA trinucleotide tail at the 3’ end of tRNAs. The comparison of the two 3D images obtained by serial crystallography reveals the local conformational changes related to the binding of the ligand in conditions that are more physiological than those used in cryo-crystallography. The protocol described in this video is generally applicable to any biomolecule, be it a protein, a nucleic acid or a multi-component complex.

PROTOCOL:

1. Setting up crystallization assays in ChipX

NOTE: The ChipX microfluidic device can be obtained from the authors. A description of the chip is given in **Figure 1**. Solutions containing the crystallant (or crystallizing agent) used to trigger crystallization may be of commercial origin or prepared by the experimenter.

1.1. Loading the biomolecule sample

NOTE: The sample volume actually required to perform an individual counter-diffusion assay in the straight section of each channel of ChipX is 300 nL. However for convenience we suggest to load 5 µL to completely fill the eight channels taking into account the variable length of their curved section and inlet dead volumes.

1.1.1. Pipet 5 µL of enzyme solutions using standard 10 µL pipet and tip.

1.1.2. Introduce the tip vertically in the sample inlet and inject the solution until the eight channels are filled up to their opposite end (entry of the crystallant reservoir).

1.1.3. Inject 1 µL of paraffin oil in the sample inlet in order to disconnect the channels from each other.

1.1.4. Recover the extra solution in the crystallant reservoir at the extremity of each channel using a standard 10 µL pipet.

1.1.5. Seal the sample inlet with a 1 cm x 1 cm piece of tape.

1.2. Loading the crystallization solutions

1.2.1. Pipet 5 µL of crystallization solution using standard 10 µL pipet and tip. The reservoir volume is 10 µL, but loading only half of it avoids overflow when sealing with tape and facilitates further addition of ligand for soaking experiments. If initial crystallization conditions were obtained by vapor diffusion, increase the crystallant concentration by a factor of 1.5 – 2. Solutions can be different in every reservoir (in the presented case, 1 M diammonium hydrogen phosphate, 100 mM sodium acetate, pH 4.5 was used throughout).

1.2.2. Orient the pipet tip towards the entry of the channel in the funnel shaped part of the reservoir to avoid the formation of an air bubble upon solution deposition. It would prevent the contact between the two solutions and crystallant diffusion into the channel.

1.2.3. Inject the crystallant solution into the reservoir.

1.2.4. Seal the reservoirs with a 2.5 cm x 1 cm piece of tape.

1.2.5. Incubate the chip at 20 °C (temperature can be adjusted depending on the target, typically between 4 and 37 °C [4]).

2. Protein labeling with carboxyrhodamine for fluorescence detection

NOTE: This step is optional. It must be performed prior to sample loading to facilitate the detection of crystals in the chip using fluorescence. The detailed method of trace fluorescent labeling was described by Pusey and coworkers[7]. All steps are carried out at room temperature.

2.1. Dissolve 5 mg of carboxyrhodamine ester powder in 1 mL anhydrous dimethyl-formamide, split the solution in 0.6 µL aliquots to be stored at -20 °C.

2.2. Prepare a 1 M Na-borate pH 8.75 stock solution.

2.3. Dilute the stock to prepare the reaction buffer at 0.05 M Na-borate pH 8.75.

2.4. Rinse a desalting column (7 kDa MWCO, 0.5 mL) with 800 µL of reaction buffer.

2.5. Centrifuge the column for 1 min at 1400 x g, remove the filtrate.

2.6. Repeat this operation twice (steps 2.4-2.5) to wash the column.

2.7. Deposit 80 µL of protein in its storage buffer on the column (the protein can be diluted down to 1 mg/mL to increase the volume if needed).

2.8. Centrifuge the column for 1 min at 1400 x g. This step is intended to transfer the protein from its storage buffer to the reaction buffer.

2.9. Recover the flow-through (containing the protein in the reaction buffer) and mix it with 0.6 µL of carboxyrhodamine solution.

2.10. Incubate 5 min at room temperature.

2.11. Meanwhile, rinse the column 3 x with the storage buffer, centrifuge the column for 1 min at 1400 x g and discard the filtrate.

2.12. Deposit the reaction solution on the column.

2.13. Centrifuge the column for 1 min at 1400 x g and recover the flow-through (i.e., solution of labeled protein in its storage buffer).

2.14. Supplement the stock protein solution with 0.1-1 % (w/w) of labeled protein.

2.15. Setup the ChipX crystallization assays as described in section 1.

2.16. Check for the presence of protein crystals in the assays by exciting the fluorescent probe with a 520 nm wavelength light source.

3. Crystal observation

NOTE: The ChipX device may be handled without special care, even with crystals inside, except if the temperature needs to be controlled.

3.1. Use any stereomicroscope to check the outcome of crystallization assays in ChipX. Its footprint has the standard dimensions of microscope slides and is compatible with any system and slide holder.

3.2. Check the content of microfluidic channels starting from the reservoir where the crystallant concentration is the highest to the sample inlet where the crystallant concentration is the lowest. The ChipX material is transparent to visible light, compatible with the use of polarizers, as well as with UV illumination for protein crystal identification by intrinsic tryptophane fluorescence[8].

3.3. Record crystal positions using the labels embossed along the channels or mark crystal locations with a permanent marker by drawing color dots next to them on the chip surface.

4. Crystal soaking with ligands

NOTE: This procedure is optional. It is used to introduce ligands, enzyme substrates or heavy atoms into the crystals and should be carried out at least 24-48 h before X-ray analysis to allow the compound diffusion along the channels and into the crystals.

4.1. Gently remove the sealing tape from the reservoirs.

4.2. Add up to 5 µL of ligand solution in one or several reservoirs using a 10 µL micropipet (in the example, 3 µL of 10 mM cytidine-5'-[(α,β)-methyleno] triphosphate (CMPcPP) solution was added to achieve a final concentration of 3.75 mM). CMPcPP is a non-hydrolizable analog of CTP, a natural substrate of the enzyme.

4.3. Seal the reservoirs with a 2.5 cm x 1 cm piece of tape.

4.4. Incubate the chip under controlled temperature for 24-48 h to allow ligand diffusion along the channels of the chip.

5. Crystal analysis by serial crystallography

NOTE: This part of the protocol needs to be adapted depending on the beamline setup and the diffraction properties of the crystals. Only general indications are given for the crystallographic analysis based on experiments performed at X06DA beamline (SLS, Villigen, Switzerland).

5.1. ChipX mounting on the beamline goniometer

NOTE: The file for 3D printing the ChipX holder is provided in ref[4].

5.1.1. Turn off the cryo-jet of the beamline. The analysis here is carried out at room temperature.

5.1.2. Mount the ChipX on a dedicated holder with the channel containing the crystals to be analyzed positioned at the center of the holder. The ChipX holder[4] does not require any screw or additional part, as it was designed to provide a perfect fit for ChipX.

5.1.3. Attach the holder to the goniometer.

5.2. Data collection

5.2.1. Orient the thickest layer (top layer, **Figure 1**) of ChipX (in this orientation labels along the channels are directly readable using the centering camera of the beamline), towards the direct beam and the thinnest face behind the crystal to minimize the attenuation of the diffracted signal as described in ref[3].

5.2.2. To avoid collision of ChipX with the surrounding material (beamstop, collimator), restrict goniometers movements in the range ±30° (0° corresponding to the channels being perpendicular to the X-ray beam).

5.2.3. Find crystals position with the help of the labels embossed along the channels.

5.2.4. Select a crystal position.

5.2.5. Center the crystal either by standard low dose grid/raster screening or 1-click procedure (the video shows an example of grid screening).

5.2.6. Collect diffraction data within the range -30° / +30°.

5.2.7. Restart the procedure at steps 5.2.4-5.2.6 on another crystal in the same channel after translation of the chip.

5.2.8. Manually realign another ChipX channel at the center of the holder and carry on data collection on crystals present in this channel.

5.2.9. Use standard crystallographic packages and procedures to process and merge the data, then to solve and refine the structure.

REPRESENTATIVE RESULTS:

The microfluidic chip described here was designed to enable easy setup of crystallization assays and crystal analysis at room temperature. The procedure described above and in the video was

applied in the frame of the structural characterization of the CCA-adding enzyme from the cold-adapted bacterium *Planococcus halocryophilus.* This enzyme belongs to an essential polymerase family that catalyses the sequential addition of the 3' CCA sequence on tRNAs using CTP and ATP[9, 10].

The chip was first used to prepare crystals of the enzyme for structural analysis by the method of counter-diffusion. To this end, the enzyme solution was loaded in the eight microfluidic channels (crystallization chambers) by a single injection in the sample inlet of the chip (see **Figure 1**). The enzyme was used at 5.5 mg/mL in its storage buffer containing 20 mM Tris/HCl pH 7.5, 200 mM NaCl and 5 mM $MgCl_2$. This step was performed manually with a standard 10 µL micropipet. Crystallization solutions (100 mM sodium acetate pH 4.5,1 M diammonium hydrogen phosphate) were then deposited in the reservoirs at the other extremity of the channels.

The loading procedure is straightforward and does not take longer than five minutes (**Figure 2**). The crystallant then diffuses into the channels, creates a gradient of concentration that triggers crystal nucleation and growth. This gradient evolves dynamically and explores a continuum of supersaturation states[5,6] until reaching an equilibrium of crystallant concentration between the channels and the reservoir. Crystallization assays are typically checked under the micoscope over a period of 2 – 4 weeks to track the growth of crystals. Bipyramidal crystals of CCA-adding enzyme appeared throughout the channels after a few days of incubation at 20 °C (**Figure 3**). The optional fluorescent labeling[7] of the protein greatly facilitates the identification of protein crystals and their discrimination from salt crystals (**Figure 4**).

We exploited the diffusive environment in chip channels to deliver a substrate to the enzyme that builds up the crystals. In the present case, CMPcPP, a CTP analog, was added to the reservoir solutions at a final concentration of 3.75 mM (**Figure 5**). This addition was performed two days before the crystallographic analysis to allow CMPcPP to reach and occupy the catalytic site of the enzyme, as later confirmed by the crystal structure (see below).

We manufactured a chip holder (**Figure 6**) in polylactic acid using a 3D printer. The holder enables chip mounting on goniometers using standard magnetic heads. Hence the chip can be easily positioned and translated in the X-ray beam to bring the crystals in diffraction position. The data collection strategy needs to be adapted depending on beamline characteristics and on crystal properties. In the case of the CCA-adding enzyme, data were collected at X06DA and X10SA beamlines, Swiss Light Source (SLS), with an X-ray wavelength of 1.0 Å and Pilatus 2M-F and 6M pixel detectors, respectively. 30-60° of rotation were collected on each crystal at room temperature with images of 0.1° or 0.2° and 0.1 s exposure (see **Table 1**). Partial datasets were processed individually and cut when the resolution of diffraction patterns started to decay due to radiation damage (detected by the decrease of signal-to-noise ratio $\langle I/\sigma(I)\rangle$ and $CC_{1/2}$, and an increase of R_{meas} in the high resolution shell). Full datasets were reconstituted by merging data from 5 crystals (**Table 1**). Crystal structures were derived by molecular replacement using standard crystallographic packages and procedures for data processing[11] and refinement[12]. The comparison of the structures of the enzyme and of its complex with CMPcPP reveals the local

conformational adaptation that accompanies substrate binding in the active site of the CCA-adding enzyme (**Figure 7**).

FIGURE AND TABLE LEGENDS:

Figure 1: **ChipX design.** The chip consists of a top layer made of COC (thickness: 1 mm) in which eight microfluidic channels and reservoirs are imprinted. The entire chip is sealed with a layer of COC (thickness: 0.1 mm). All channels are connected to a single inlet on the left hand side for simultaneous sample injection and to individual reservoirs on the right hand side in which crystallization solutions are deposited. The channels, which constitute the actual crystallization chambers of the chip, are 4 cm long and have a cross section of 80 µm x 80 µm. Labels (A1, A2, A3, etc.) embossed along the channels facilitate crystal positioning under the microscope and the preparation of a sample list for data collection. ChipX has the size of a standard microscope slide (7.5 cm x 2.5 cm).

Figure 2: **Setting up crystallization assays in ChipX.** 1) Deposit 5-6 µL of enzyme solutions using standard 10 µL pipet and tip. 2) Introduce the tip vertically in the sample inlet and inject the solution in the eight channels. 3) Pipet 1 µL of paraffin oil. 4) Introduce the tip vertically in the sample inlet and inject the oil in order to disconnect the channels from each other. 5) Seal the inlet with a piece of tape. 6) Pipet 5 µL of crystallization solution using standard 10 µL pipet and tip. Solutions can be different in every reservoir (e.g., from a screening kit). 7) Orient the pipet tip towards the entry of the channel in the funnel shaped part of the reservoir (to avoid the formation of an air bubble upon solution deposition) and inject the crystallant solution in the reservoir. 8) Seal the reservoirs with a piece of tape and incubate the chip at controlled temperature.

Figure 3: Crystals of CCA-adding enzyme grown by counter-diffusion in the microfluidic channels of ChipX. Scale bar is 0.1 mm.

Figure 4: **Crystal soaking procedure.** 1) Gently remove the tape from the reservoirs. 2) Deposit up to 5 µL of ligand solution using a 10 µL micropipet. 3) Add the ligand to one or several reservoirs. 4) Seal again the reservoirs with a piece of tape and incubate the chip under controlled temperature for 24-48 h before data collection.

Figure 5: **Trace fluorescent labeling discriminates protein (left) from salt (right) crystals.** The CCA-adding enzyme solution contained 0.4 % (w/w) of protein labeled with carboxyrhodamine. On the right, crystals are illuminated with a 520 nm wavelength light source and the image is taken with a low pass filter at 550 nm (LP550); (inset) structure of carboxyrhodamine-succinimidyl ester.

Figure 6: **(Left) Drawing of the ChipX holder and (Right) ChipX mounted on the goniometer of beamline X06DA at SLS (Villigen, Switzerland) for serial crystal analysis.**

Figure 7: Comparison of CCA-adding enzyme active site in the apo form (in pink) and in the complex with a CTP analog (in green). Although the overall conformation of the enzyme is not

affected, the binding of the CMPcPP ligand is accompanied by a slight reorganization of side chains in the active site. The 2*Fo-Fc* electron density map (in blue) is contoured at 1.2 sigma. The difference electron density map contoured at 4 sigma (in green) confirms the presence of the ligand in the active site.

Table 1: Data collection and refinement statistics

§ Redundancy-independent $Rmeas = \Sigma_{hkl} (N/N-1)^{1/2} \Sigma_i |I_i(hkl) - \langle I(hkl)\rangle| / \Sigma_{hkl} \Sigma_i I_i(hkl)$, where N is the data multiplicity [17].

£ Data with low $\langle I/\sigma(I)\rangle$ in outer shell (<2.0) were included based on CC1/2 criterion (correlation between two random halves of the dataset > 50%) as proposed by Karplus & Diederichs [18].

DISCUSSION:

Current protocols in biocrystallography involve the preparation of crystals using methods such as vapor diffusion or batch[13, 14], and their transfer into a microloop for cryo-cooling[15, 16] before performing the diffraction analysis in a nitrogen jet at cryogenic conditions. In contrast, direct crystal cryo-cooling is not possible in ChipX[3] and crystals cannot be extracted from their microfluidic channel, which can be seen as limitations of this setup. However, the protocol described in the article provides a fully integrated pipeline for the determination of crystal structures at room temperature (i.e., in more physiological conditions). Even though data collection at room-temperature causes an increase of radiation damage[19], this effect is counterbalanced by fast data acquisition time (a maximum of 60° rotation is collected on each crystal) and by merging of several partial datasets. Both ChipX design and material were optimized to reduce background scattering and diffraction signal attenuation[3], and data collection can be performed on crystals with dimensions equivalent to half the size of the channels (40 µm)[4].

To summarize, the main advantages of the protocol are the following. The crystals are produced in a convection-free environment (microfluidic channels), which is very favorable to the growth of high-quality crystals. The counter-diffusion method implemented in ChipX is very efficient at screening the supersaturation landscape; the diffusion of crystallants into the chip channel creates a concentration and supersaturation wave that helps determine appropriate nucleation and growth conditions[5]. Crystals are never directly handled, but are analyzed in situ, inside the chip, which preserves their genuine diffraction properties (i.e., does not alter crystal mosaicity by physical interaction or cryocooling)[20]. The diffraction analysis is performed on a series of crystals distributed along the chip channels with low dose exposure to minimize radiation damage, and a full dataset is assembled by merging partial data from the series. The standard footprint and simple design of ChipX will allow in the future a complete automation of *in situ* data collection using synchrotron or XFEL facilities. All steps of the protocol are carried out in ChipX. From the experimenter point-of-view, chip setup is simple and easy to perform with standard pipets and does not require any extra equipment. The tree-like channel connection at the sample inlet minimizes dead volumes in the system, which is important when working with samples that are difficult to purify or that are only available in limited quantity.

In conclusion, the lab-on-a-chip approach implemented in ChipX simplifies and efficiently miniaturizes the process of crystallization by counter-diffusion and crystal structure determination, allowing to go from the sample to its 3D structure in a single device. It is widely applicable and offers a user-friendly, cost-effective solution for routine serial biocrystallography investigations at room temperature.

ACKNOWLEDGMENTS:

The authors acknowledge the Swiss Light Source (Villigen, Switzerland) for beamtime allocation to the project on beamlines X10SA (PXII) and X06DA (PXIII), Alexandra Bluhm for her contribution to structure refinement, Clarissa Worsdale for the recording of the voiceover and François Schnell (Université de Strasbourg) for his assistance in video editing and SFX. This work was supported by the French Centre National de la Recherche Scientifique (CNRS), the University of Strasbourg, the LabEx consortium "NetRNA" (ANR-10-LABX-0036_NETRNA), a PhD funding to R.dW from the Excellence initiative (IdEx) of the University of Strasbourg in the frame of the French National Program "Investissements d'Avenir", a PhD funding to K.R. from the French-German University (UFA-DFH, grant no. CT-30-19), the Deutsche Forschungsgemeinschaft (grant no. Mo 634/10-1). The authors benefitted from the PROCOPE Hubert Curien cooperation program (French Ministry of Foreign Affair and Deutscher Akademischer Austauschdienst).

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. Giegé, R., Sauter, C. Biocrystallography: past, present, future. *HFSP Journal*. **4** (3–4), 109–121 (2010).
2. Dhouib, K. et al. Microfluidic chips for the crystallization of biomacromolecules by counter-diffusion and on-chip crystal X-ray analysis. *Lab on a Chip*. **9** (10), 1412–1421 (2009).
3. Pinker, F. et al. ChipX: A Novel Microfluidic Chip for Counter-Diffusion Crystallization of Biomolecules and in Situ Crystal Analysis at Room Temperature. *Crystal Growth & Design*. **13** (8), 3333–3340 (2013).
4. de Wijn, R. et al. A simple and versatile microfluidic device for efficient biomacromolecule crystallization and structural analysis by serial crystallography. *IUCrJ*. **6** (3), 454–464S2052252519003622 (2019).
5. García-Ruiz, J.Ma. et al. A supersaturation wave of protein crystallization. *Journal of Crystal Growth*. **232** (1–4), 149–155 (2001).
6. Otálora, F., Gavira, J.A., Ng, J.D., García-Ruiz, J.M. Counterdiffusion methods applied to protein crystallization. *Progress in Biophysics and Molecular Biology*. **101** (1–3), 26–37 (2009).
7. Pusey, M., Barcena, J., Morris, M., Singhal, A., Yuan, Q., Ng, J. Trace fluorescent labeling for protein crystallization. *Acta Crystallographica Section F Structural Biology Communications*. **71** (7), 806–814 (2015).
8. Meyer, A., Betzel, C., Pusey, M. Latest methods of fluorescence-based protein crystal identification. *Acta Crystallographica Section F Structural Biology Communications*. **71** (2), 121–131 (2015).

9. Betat, H., Rammelt, C., Mörl, M. tRNA nucleotidyltransferases: ancient catalysts with an unusual mechanism of polymerization. *Cellular and Molecular Life Sciences*. **67** (9), 1447–1463 (2010).
10. Ernst, F.G.M., Erber, L., Sammler, J., Jühling, F., Betat, H., Mörl, M. Cold adaptation of tRNA nucleotidyltransferases: A tradeoff in activity, stability and fidelity. *RNA Biology*. **15** (1), 144–155 (2018).
11. Kabsch, W. XDS. *Acta Crystallographica. Section D, Biological Crystallography*. **66** (2), 125–132 (2010).
12. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallographica. Section D, Biological Crystallography*. **66** (2), 213–221 (2010).
13. Dessau, M.A., Modis, Y. Protein Crystallization for X-ray Crystallography. *Journal of Visualized Experiments*. **47**, doi: 10.3791/2285 (2011).
14. Sauter, C., Lorber, B., McPherson, A., Giegé, Richard Crystallization - General Methods. *In International Tables of Crystallography, Vol. F, Crystallography of Biological Macromolecules (2nd edition), E. Arnold, D.M. Himmel & M.G. Rossmann (eds)*. 99–120 (2012).
15. Garman, E. "Cool" crystals: macromolecular cryocrystallography and radiation damage. *Current Opinion in Structural Biology*. **13** (5), 545–551 (2003).
16. Li, D., Boland, C., Aragao, D., Walsh, K., Caffrey, M. Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography. *Journal of Visualized Experiments*. **67**, doi: 10.3791/4001 (2012).
17. Diederichs, K., Karplus, P.A. Improved R-factors for diffraction data analysis in macromolecular crystallography. *Nature Structural Biology.* **4** (4), 269–275 (1997).
18. Karplus, P.A., Diederichs, K. Linking Crystallographic Model and Data Quality. *Science*. **336** (6084), 1030–1033, (2012).
19. de la Mora, E., Coquelle, N., Bury, C.S., Rosenthal, M., Holton, J. M., Carmichael, I., Garman, E. F., Burghammer, M., Colletier, J-P., and Weik, M. Radiation damage and dose limits in serial synchrotron crystallography at cryo- and room temperatures. *Proceedings of the National Academy of Sciences of the United States of America*. **117** (8), 4142-4151 (2020).
20. Nave, C. A., Description of Imperfections in Protein Crystals. *Acta Crystallographica. Section D, Biological Crystallography*. **54** (5), 848–853 (1998).

421

Figure 1



Figure1new.png

Figure 2

Click here to access/download;Figure;Figure2.tif

Figure2.png



Figure 3

Click here to access/download;Figure;Figure3.tif



Figure3.png

Figure 4



Figure4.png

Figure 5

Click here to access/download;Figure;Figure5.tif



Figure5.png

Figure 6

Click here to access/download;Figure;Figure6.tif



Figure6.png



Figure7.tif

Crystallized sample	**CCA-adding enzyme**	**CCA-adding enzyme + CMPcPP**
Crystal analysis		
X-ray beamline	SLS – X06DA	SLS – X10SA
Wavelength (Å)	1.000	1.000
Temperature (K)	293	293
Detector	Pilatus 2M-F	Pilatus 6M
Crystal-detector distance (mm)	300	400
Crystals collected	6	14
Crystals selected	5	5
Rotation range per image (°)	0.1	0.2
Exposure time per image (s)	0.1	0.1
No. of images selected	1000	540
Total rotation range (°)	100	108
Space group	$P\,4_32_12$	$P\,4_32_12$
a , c (Å)	71.5, 293.8	71.4, 293.6
Mean mosaicity (°)	0.04	0.04
Resolution range (Å)	46 – 2.54 (2.6 – 2.54)	48 – 2.3 (2.4 – 2.3)
Total No. of reflections	176105 (9374)	232642 (32937)
No. of unique reflections	23922 (1598)	34862 (4066)
Completeness (%)	90.6 (84.6)	99.5 (100.0)
Redundancy	7.5 (6.0)	6.7 (8.1)
$\langle I/\sigma(I)\rangle$	8.1 (1.3)	6.9 (0.7)
R meas (%) §	18.6 (126.0)	18.0 (231.2)
CC1/2 (%) £	98.7 (55.0)	98.7 (46.9)
Overall B factor from Wilson plot (Å^2)	57.4	60.6
Crystallographic refinement		
No. of reflections, working set / test set	23583 / 1180	34840 / 3405
Final Rcryst (%) / R_{free} (%)	18.8 / 21.4	20.0 / 22.9
No. of non-H atoms: overall / protein / ligand / solvent	2998 / 2989 / 0 / 9	3057 / 2989 / 29 / 10
R.m.s. deviations for bonds (Å) / angles (°)	0.009 / 1.23	0.010 / 1.22
Average B factors (Å^2): overall / protein / ligand / solvent	60.1 / 60.1 / 0 / 52.7	62.5 / 62.6 / 60.1 / 55.5
Ramachandran plot: most favored (%) / allowed (%)	98.1 / 1.9	97.2 / 2.8
PDB id	6IBP	6Q52

Name of Material/Equipment	Company	Catalog Number	Comments/Description
Axioscope A1 stereomicroscope	Zeiss		Crystal observation (step 3)
Carboxyrhodamine succinimidyl ester	Invitrogen	C-6157	Protein labeling (step 2)
CMPcPP	Jena Bioscience	NU-438	Crystal soaking (step 4)
Crystal clear sealing tape	Hampton research	HR3-511	ChipX sealing (step 1)
Parafin oil	Hampton research	HR3-411	ChipX loading (step 1)
Ultimaker 2 extended+	Ultimaker		3D printer - Representative results
UV light source	Xtal Concepts Gmbh	XtalLight100c	Crystal observation (step 3)
Zeba spin desalting column 7K MWCO	ThermoFisher Scientific	89882	Protein labeling (step 2)

Answers to reviewers' and editors' comments

We would like to thank the reviewers and the editorial board for their very constructive comments. All of them were taken into account to revise the manuscript and the video. Changes in the revised text are highlighted in red, as well as our answers below.

Editorial and production comments

Changes to be made by the Author(s) regarding the written manuscript:
1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. Done
2. Please revise the title for conciseness. Please reflect the revised title in the video as well. The title has been shorten
3. How can one obtain/get the ChipX? A sentence has been inserted in Step 1. to indicate that ChipX can be obtained from the authors
4. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials. Done (all product names are referenced in the Table of Materials)
5. Please add more details to your protocol steps. Please ensure you answer the "how" question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action. Done (see below)
6. Please provide an example for the protocol instead of a generalized protocol. We need specific values throughout. The protocol has been updated accordingly
7. What enzyme solution is used and at what concentration? Done
8. 1.1.5: What are the dimensions of the piece of tape? Done
9. 1.2.5: Incubate at what temperature? Done
10. 2.15: As described where? Done
11. Please provide the diffraction data collection parameters. Done (see representative results and table 1)
12. Please discuss some limitations of the protocol in the discussion. Done

Changes to be made by the Author(s) regarding the video:
1. Video Editing Notes
• 01:15 Directly after the chapter title card leaves the screen, there is a black flash frame before the animation of the X3 chip. Consider using a fade down to and from white and eliminate the black flash frame. Done
• 04:10 Similar issue here as 01:15. Avoid flashing black or white frames. Consider fading down to white and fading back up to the chapter title card. Done
• 04:47 It looks like the outgoing image of the channel with the crystal in it is being matched to the incoming closeup of the channel. A neat idea, but perhaps increase the duration of the dissolve (fading across two shots/images), as right now it seems "glitchy" instead of smooth, because the incoming image appears too quickly. Done

• 05:02 This transition could use a little work as well, similarly to the other title card transitions. The fading out of the graphics should complete before the fading in of the chapter title card. Done
• 09:55 Black flash frame right before chapter title card Done
• 10:01 The background behind Raphael here shifts or jerks a bit at the beginning. Consider starting playback a little later to trim out the glitch Done
• 10:30 The dubbing here is a little obvious. Try applying some frequency equalization to his voice to knock out the low-ends / bass to try better match the original audio. Some reverb might help too (the dubbing sounds too "clean" compared to the live audio recorded by Claude Done

Please upload a revised high-resolution file here:
https://www.dropbox.com/request/zE6EOlNMqYYH4PC3Panj?oref=e

Reviewer #1:

Manuscript Summary:
This paper describes a method of using the ChipX counter-diffusion microfluidic device for the crystallization, potential ligand soaking, and then in situ room temperature X-ray diffraction data collection of protein crystallography data.

Major Concerns:
1. Line 118: In Step 10 of the labeling protocol, why is the flow-through from the spin column recovered? Perhaps there is a difference in terminology here, but to me the "flow-through" would be the filtrate that passes through the filter (thus lacking protein), rather than the retentate (containing protein) that sits above the filter.

Related to this point, the authors could specify a "protein containing" solution where relevant for emphasis.

The procotol is correct and corresponds to the original one published by Pusey and coll. (ref 7). The column is a desalting device used to exchange the buffer and the protein is recovered in the flow-through. We rephrased this part to better indicate in which buffer the protein is.

2. The authors provided useful guidelines for adapting crystallization conditions from vapor diffusion to counter diffusion. Can they also comment on the potential importance (or lack thereof) of inspecting samples over time? Depending on the crystallization conditions the counter diffusion concentration gradient could take hours or days to develop and ultimately stabilize. How important is this transient period in terms of successful crystallization results as compared to vapor diffusion?
Related to this point, would it be useful/informative to describe how the location in the channel where crystals form can be correlated to a specific concentration. For instance, where in the channel did the crystals of the CCA-adding enzyme form? Done (representative results and discussion).

3. In the procedural discussion related to ligand soaking and Figure 4, it might be useful to specify the total volume of the reservoir. Based on the schematic, I assume that 5 µL of crystallization would not be enough to fill up the well. Perhaps 10 µL would not fill the reservoir either. At what point should the user be concerned about overflow? Done (see 1.2.1)
4. How is the device secured to the chip holder for X-ray analysis? Are there set screws? Please clarify this part of the procedure and any relevant considerations. Done (see 5.1)
5. For users who are not familiar with room temperature data collection, are there any considerations and/or indications of data quality lost that would be useful to communicate? Done (representative results and discussion)
6. The authors state that "the counter-diffusion method implemented in ChipX is very efficient at screening the supersaturation landscape and at finding nucleation and growth conditions." While I absolutely agree, this statement is given without explanation. I do not think that a detailed discussion of this point belongs in this type of protocol paper, but it might be useful to refer the reader to papers where they can read more about this aspect of the method. Done (see discussion)
7. Similarly, the statement that crystal quality is preserved by avoiding physical handling could be supported by references. Done
8. How is the volume needed for an individual counter-diffusion experiment in ChipX only 300 nL if 5-6 µL are needed to fill the chip? Done (explained in 1.1)
9. Can the authors comment about any general trends in the usability of their device with regards to successful data collection on small crystals? There is a certain amount of background scattering and signal attenuation associated with the device. Are they able to collect data on crystals that are equal in size to the thickness of the device? Half of that? What is known? Done (see discussion)

Minor Concerns:
1. In the Introduction, please clarify that the acryonym 'CCA' in CCA-adding enzyme refers to a nucleotide sequence. I did not realize this until I got to the more detailed description in the representative results section. A sentence was added in the introduction
2. Line 87: When talking about "recovering the extra solution in the crystallant reservoir," would the authors please comment on the method used for this? Are standard pipets sufficient? Is there any particular technique involved? Done
3. Line 134: the use of the term "binocular" in this context seems odd. I think of binoculars as being used to magnify things at a distance. Perhaps the description "stereomicroscope" could be used in place of binoculars, and differentiated from the already mentioned "microscope" as an inverted/upright microscope? Done
4. Lines 175-176: The discussion of chip orientation with respect to the X-ray beam could be improved via reference to a figure that more clearly highlights the device architecture. Done
5. Line 232: The phrase "The whole is sealed" was unclear. Are the authors referring to the entire device or holes in the device? Done
6. In the caption for Figure 1 I might suggest specifying right/left in the image for the single inlet vs. the crystallization solutions, rather than "one side" and "the other side." Done

7. In Figure 1 we can easily discern the ABCD labels for each of the channels. However, it is unclear what the smaller labels along the length of each channel are. Would the authors please include an inset image that highlights this aspect of their device? (One might also consider showing a photograph, rather than just the schematic). Done. This point is nicely illustrated in the movie (see 4:15)
8. It might be useful for the authors to label some key residues in their electron density map in Figure 7 to give readers who are not intimately familiar with this protein a point of reference. Done

Reviewer #2:
Manuscript Summary:
The purpose of this video is to grow protein crystals in microfluidic channels using the diffusion technique. Protein crystals can be measured directly in X-ray beam without any extra steps for crystal handling.

Major Concerns:
I do not have any major concerns and I like this ChipX techniques.

Minor Concerns:
All steps in the video are very clear to follow up and all expiations from the beginning to the end are easily understood. In the section II and III (2:26 to 4:10), it would be much better if the view could be zoomed in more to see the loading the process.

Zoomed views have been inserted in the video as suggested at 2:30 and 3:27.

jove JOURNAL OF VISUALIZED EXPERIMENTS
1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Crystallization and structural determination of an enzyme:substrate complex by serial crystallography in a user-friendly and versatile microfluidic chip
Author(s):	R. de Wijn, K. Rollet, V. Olieric, O. Hennig, N. Thome, C. Nous, C. Paulus, B. Lorber, H. Betat, M. Mörl, C. Sauter

Item 1: The Author elects to have the Materials be made available (as described at http://www.jove.com/publish) via:

☐ Standard Access ☑ Open Access

Item 2: Please select one of the following items:

☑ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and(c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.